0      0

AM23-ST-18-O - AM23-ST-18-O: Potential Role of Intravenous Hemostatic Agents/Adjuncts in Pediatric Trauma: A Review of the Evidence for (or Against) Their Use (Enduring)

‐ Oct 18, 2023 5:00pm

Credits: None available.

This session will focus on the role of anti-fibrinolytics and other hemostatic agents/adjuncts (such as prothrombin concentrates, rFVIIa, fibrinogen concentrates/cryoprecipitate) in controlling bleeding and lowering transfusion needs in pediatric trauma situations. Key animal experimental studies and pediatric/adult clinical studies that support its use in attenuating bleeding in pediatric patients will be presented. In addition, assays that can guide the use of hemostatic agents/adjuncts will be described.

Learning Objectives:

  • Understand the difference in hemostasis between children and adults.
  • Describe the evidence for (or against) the use of tranexaminc acid in pediatric trauma and non-trauma bleeding situations.
  • Describe the evidence for (or against) the use of other hemostatic agents/adjuncts such as prothrombin concentrates (PCC) and other hemostatic agents (eg. rFVIIa, fibrinogen concentrates/cryoprecipitate) in pediatric trauma.
  • Describe assays that can guide use of these agents/adjuncts in bleeding pediatric patients.




  • Marian Rollins-Raval, MD:
    Precision Biologic: Grant/Research Support (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing); Siemens: Speaker's Bureau (Ongoing)
  • Phillip Spinella, MD:
    Cerus: Consultant/Advisory Board (Ongoing); Haima: Consultant/Advisory Board (Ongoing); Hemanext: Consultant/Advisory Board (Ongoing); Kalocyte: Stock Shareholder (self-managed) (Ongoing); Octapharma: Consultant/Advisory Board (Ongoing)
  • Edward Wong, MD:
    Quest Diagnostics: Stock Shareholder (self-managed) (Ongoing)


Credits: None available.